

## **What partners of the “AMP RA/SLE” are saying...**

### **AbbVie**

“When it comes to figuring out what is driving autoimmune diseases like Rheumatoid Arthritis and Lupus, we are all in this together. Through tissue and blood sample analysis from people with RA and Lupus, we’re hoping to identify differences between those with RA who respond to therapies and those who do not, as well as provide a better systems-level understanding of disease mechanisms in both RA and Lupus. The ultimate goal of extending this partnership is to increase the number of new diagnostics and therapies for patients.” – Lisa Olson, Ph.D., Vice President, Immunology Research, AbbVie Bioresearch Center

### **Arthritis Foundation**

“The cost of developing new therapies is only exceeded by the cost of failing to do so. As a countermeasure to this, partnership in early stage research is essential and allows health innovators to efficiently create the understandings that inspire future therapies for people with rheumatoid arthritis and SLE. These are tools for the toolmakers, but incredibly important in the progress to create new medicines.” – Guy Eakin, Ph.D., Senior Vice President of Scientific Strategy, Arthritis Foundation

### **Bristol-Myers Squibb Company**

"Bristol-Myers Squibb is proud to be taking part in AMP RA/SLE. The research being conducted will open new avenues for translational research in RA and lupus, and, we hope, accelerate the development of new therapies for patients with these serious diseases." – Mary Beth Harler, M.D., Senior Vice President and Head of Innovative Medicines Development, Bristol-Myers Squibb Company

### **Foundation for the National Institutes of Health**

“With the additional participation in AMP RA/SLE from our private sector partners, we have a unique opportunity to further analyze the samples from RA and lupus patients at the single cell level using scRNA-seq. These results will further help researchers to advance critical research on new drug targets and therapies for autoimmune diseases.” – David Wholley, Senior Vice President, Research Partnerships, Foundation for the National Institutes of Health

### **Lupus Research Alliance**

“The Lupus Research Alliance is delighted with the extension of the AMP RA/SLE initiative, which offers a unique opportunity to generate a much richer dataset utilizing valuable patient samples and employing state of the art technologies. We anticipate that this effort will not only provide further insights about disease development, but may identify targets for therapeutic intervention, potential biomarkers and may ultimately aid in the molecular classification of these important diseases.” – Teodora Staeva, Ph.D., Research Director, Lupus Research Alliance

### **National Institute of Arthritis and Musculoskeletal and Skin Diseases**

“This collaborative effort has yielded fresh insights into the molecular underpinnings of rheumatoid arthritis and lupus. Using cutting edge-technologies, AMP investigators have identified previously unrecognized cell populations, aberrant cell subsets and pathways that may be relevant to these diseases. The project catalyzed the capacity to obtain and conduct research on tissue in the United States. We are excited to leverage the significant investments already made in this program to further our quest for tailored treatments for people with these diseases.” – Stephen I. Katz, M.D., Ph.D., Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases

### **Rheumatology Research Foundation**

“We are proud to be a partner of the AMP program and are thrilled with the discoveries already made through this collaboration. These advancements hold clues for potential research targets that may lead to future treatment options for millions of patients, and that’s critical to our mission of improving the health of everyone living with a rheumatic disease.” – Mary Wheatley, Executive Director of the Rheumatology Research Foundation

### **Sanofi**

“We are delighted that the Accelerating Medicines Partnership (AMP) is extending the AMP RA/SLE program through 2020, and we are proud to support this important initiative. We are very passionate about advancing new medicines for immune-mediated inflammatory conditions including rheumatoid arthritis. Our core philosophy is that breakthrough therapies will only be achieved through a deeper understanding of the biology and molecular pathways that drive these conditions. The AMP RA/SLE program has already made great strides in adding to the scientific community’s body of knowledge in this area, and we look forward to its continued progress.” – Frank Nestle, M.D., Global Head of Immunology and Inflammation Research, and Chief Scientific Officer, North America, Sanofi